ISSN 2564-7784 | E-ISSN 2564-7040
Original Article
Effect of Intravenous Nitrate Treatment on Serum BNP Level and 30-Day Follow-up Events in Decompensated Systolic Heart Failure
1 Department of Cardiology, Health Sciences University, Adana Numune Training and Research Hospital, Adana, Turkey  
Gaziantep Med J ; : -
DOI: 10.5152/EurJTher.2017.207
This article was viewed 56 times, downloaded 0 times

Key Words: Intravenous nitrate, systolic heart failure, B-type natriuretic peptide
Abstract

Objective: The aim of this study is to evaluate the potential of intravenous (I.V) nitroglycerine (NTG) administration to accelerate the reduction of B-type natriuretic peptide (BNP) levels in patients with decompensated systolic heart failure (HF) and to evaluate its impact on follow-up events.

 

Methods: A total of 165 patients with systolic HF who were hospitalized due to acute decompensation were enrolled to the current study. Study patients were divided into two groups. Patients who were taking standard HF therapy (ACE or ARB, beta-blockers, loop diuretics and anticoagulant or antiaggregant agents for venous prophylaxis) were called as standard HF therapy group (n=72) and, patients using a standard dose of IV NTG in addition to standard HF therapy served as the IV NTG group (n=93). BNP levels and blood gas analyses were measured at admission and after 48 hours and all patients were followed up along the first month after discharge.

 

Results: Serum BNP levels decreased in all patients after 48 hours. The decreasing of BNP level was higher and the improvement of blood gas analysis was better in the IV NTG group than in the standard therapy group (1347.1±314.3 vs 280.0±196.2 pg/mL for IV NTG group and 1178.3±305.5 vs 495.4±229.9 pg/mL for Standard therapy group; p<0.001). In the multi-logistic regression analysis, serum sodium at admission, BNP level at 48 hours, and use of IV NTG were found as predictors of 30-day follow-up events.

 

 

Conclusion: We have shown that IV NTG therapy in addition to standard HF therapy has a markedly better effect on lowering of plasma BNP levels, improves blood gas analyses, and may reduce follow-up events in patients with systolic HF. 

Key Words
Authors
All
Survey
AVES | Copyright © 2017 European Journal of Therapeutics | Latest Update: 04.10.2017